[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 438
Citations 0
Research Letter
June 2016

Patients With Psoriasis and Personalized Trade-offs in Treatment Decisions—Lessons Learned From Focus Groups

Author Affiliations
  • 1Laboratory for Investigative Dermatology, The Rockefeller University, New York, New York
  • 2Christine Frank and Associates: Research and Evaluation, Barrie, Ontario, Canada
  • 3Center for Clinical and Translational Science, The Rockefeller University, New York, New York
JAMA Dermatol. 2016;152(6):720-722. doi:10.1001/jamadermatol.2016.0501

Psoriasis is a common debilitating disease for which there are many treatment options, creating complex choices for patients and clinicians. Patient decision aids (PDAs), decision-supporting tools that facilitate shared decision-making, may engender a collaborative process between physician and patient. The design of PDAs typically focuses on conveying information about evidence-based treatment options and the value-sensitive nature of the decisions.1,2 To help patients better align treatment choices with their personal values, the specifics of patient treatment preferences must be more elaborately embedded into the design of PDAs.3,4 We undertook detailed assessment of treatment decision-making experiences of patients with psoriasis to discover key patient preferences that can be incorporated into a subsequent PDA design for these patients.

First Page Preview View Large
First page PDF preview
First page PDF preview